Clinical Significance of the Augmentation Index in Patients with Preserved Kidney Function

Takashi Hitsumoto

Hitsumoto Medical Clinic, Yamaguchi

Abstract

Background: The augmentation index (AIx) indicates arterial wave reflection. Clinical studies have shown a relationship between an elevated AIx and cardiovascular disease. This cross-sectional study attempted to clarify the clinical significance of AIx in patients with preserved kidney function.

Patients and Methods: The subjects were 321 patients with preserved kidney function (an estimated glomerular filtration rate ≥ 60 mL/min/1.73 m² and normoalbuminuria) but with no history of cardiovascular events. The AIx was determined in the radial artery by means of tonometry, and the relationships of the AIx to kidney function and markers of atherosclerosis were examined.

Results: A significant positive correlation ($r=0.30$; $p<0.001$) was found between the AIx and the urinary albumin concentration. The AIx showed a significant positive correlation ($r=0.28$; $p<0.001$) with the serum high-sensitivity C-reactive protein concentration, as a marker of inflammation; with the urinary 8-iso-prostaglandin F_{2 α} concentration ($r=0.31$; $p<0.001$), as a marker of oxidative stress; and with the cardio-ankle vascular index ($r=0.17$; $p<0.01$), as a marker of systemic arterial stiffness. Multiple regression analysis indicated that the urinary 8-iso-prostaglandin F_{2 α} concentration ($t=5.1$; $p<0.001$), serum high-sensitivity C-reactive protein concentration ($t=4.9$; $p<0.001$), and urinary albumin concentration ($t=3.6$; $p<0.01$) were independent variables for AIx after adjustment.

Conclusion: These findings indicate that the AIx reflects inflammation, oxidative stress, and the urinary albumin concentration in patients with preserved kidney function.

(J Nippon Med Sch 2012; 79: 422–429)

Key words: augmentation index, preserved kidney function, inflammation, oxidative stress, urinary albumin concentration

Introduction

Chronic kidney disease, which is usually diagnosed on the basis of a decreased estimated glomerular filtration rate (eGFR) or the presence of proteinuria/

microalbuminuria or both, is a risk factor for both end-stage renal disease and cardiovascular disease^{1,2}. Furthermore, from the perspective of preventive medicine, treatment strategies for kidney disease and atherosclerosis should be considered while kidney function is still normal or in the early phase

Correspondence to Takashi Hitsumoto, Hitsumoto Medical Clinic, 2-7-7 Takezaki-cho, Shimonoseki, Yamaguchi 750-0025, Japan

E-mail: thitsu@jcom.home.ne.jp

Journal Website (<http://www.nms.ac.jp/jnms/>)

Fig. 1 Measurement of augmentation index

The augmentation index was determined with subjects in the sitting position by means of a commercial device (HEM-9010AI; Omron Healthcare, Kyoto, Japan). The augmentation index is automatically calculated as $P2/P1 \times 100\%$. The P1 and P2 indicate the height of the early and late systolic peaks, respectively.

of kidney disease³.

The augmentation index (AIx) indicates arterial wave reflection⁴. Clinical studies have shown that an elevated AIx and an elevated central blood pressure are important predictors of cardiovascular disease⁵⁻⁸. However, little is known about the clinical significance of the AIx in patients with preserved kidney function. Here, author examined the relationships of AIx to kidney function and to markers of atherosclerosis to clarify the clinical significance of the AIx in patients with preserved kidney function.

Materials and Methods

1. Subjects

This cross-sectional study was performed at the Hitsumoto Medical Clinic in Shimonoseki from December 2007 through November 2009. The AIx and various clinical variables were analyzed in 321 consecutive patients with lifestyle-related diseases and preserved kidney function. Kidney function was considered to be preserved if the eGFR was at least 60 mL/min/1.73 m² and if normoalbuminuria was present (urinary albumin concentrations < 30 mg/g creatinine). Patients with a history of cardiovascular events, chronic atrial fibrillation, or peripheral artery

disease (ankle-brachial index <0.9) were excluded. All patients gave informed consent, and the study protocol was approved by the local ethics committee of Hitsumoto Medical Clinic.

2. Determination of the AIx and Blood Pressure

The blood pressure and the AIx were determined in a room with the temperature maintained at 20°C to 25°C. Treatment with antihypertensive drugs was stopped 24 hours or more before measurement. The radial AIx was determined with the subject in the sitting position by means of an applanation tonometry-based device (HEM-9010 AI; Omron Healthcare Co., Ltd., Kyoto, Japan; **Fig. 1**). This technique has been described in detail previously^{4,9}. Briefly, the tonometry sensor unit is a pressure sensor composed of an array of 40 microtransducer elements. When the unit is placed on a patient's wrist, 1 of the 40 sensor elements is automatically selected to obtain optimal radial pressure waveforms. The first and second systolic peaks are automatically detected, and, consequently, the AIx is calculated. The validity and reliability of radial AIx measurement with this method are well established: several studies have indicated a close linear correlation between the radial AIx and the central AIx^{4,8,9}. In addition, the right brachial blood pressure

and pulse rate were automatically measured twice with the oscillometric approach. The average of 2 readings was used to determine systolic and diastolic blood pressures and the pulse rate.

3. Evaluation of Kidney Function

The eGFR and the urinary albumin concentration were measured as indicators of kidney function. The eGFR was calculated with the adjusted Modification of Diet in Renal Disease study equation, proposed by the working group of the Japanese Chronic Kidney Disease Initiative¹⁰. The urinary albumin concentration was measured with the latex agglutination method and normalized to urinary creatinine concentration.

4. Evaluation of Cardiovascular Risk Factors

Hypertension was diagnosed if the systolic blood pressure was at least 140 mmHg, if the diastolic blood pressure was at least 90 mmHg, if the subject was receiving antihypertensive treatment, or any combination of these factors. Hyperlipidemia was diagnosed if the serum low-density lipoprotein cholesterol concentrations was at least 140 mg/dL, if serum triglyceride concentrations at least 150 mg/dL, or if the subject was receiving antihyperlipidemic treatment, or any combination of these factors. Diabetes mellitus was diagnosed if the fasting blood glucose levels were at least 126 mg/dL, if the subject had a history of diabetes mellitus or was receiving antidiabetic treatment, or any combination of these factors. Obesity was estimated by the body-mass index. Smoking was considered positive if subjects smoked cigarettes habitually at the start of the study. Blood samples were collected from the antecubital vein in the morning after 12 hours of fasting. Concentrations of serum lipids, plasma glucose, plasma insulin, and serum high-sensitivity C-reactive protein (hs-CRP) were subsequently measured. Total cholesterol and triglyceride concentrations were measured with standard enzymatic methods. The high-density lipoprotein cholesterol concentration was measured by means of selective inhibition. The concentration of low-density lipoprotein cholesterol was calculated with Friedewald's formula¹¹. The glucose

concentration was measured with the glucose oxidase method, and insulin levels were measured with an enzyme immunoassay. The hemoglobin A1c was measured with standard laboratory procedures. To measure insulin resistance, the homeostatic model assessment of insulin resistance (HOMA-IR) was used as follows¹²: $\text{HOMA-IR} = \frac{\text{fasting glucose concentration [mg/dL]} \times \text{fasting insulin concentration [\mu g/mL]}}{405}$. The hs-CRP concentration was measured with high-sensitivity, latex-enhanced immunonephelometrics. The urinary 8-iso-prostaglandin F2 α concentration was also measured, as an oxidative stress marker, with an enzyme immunoassay in urine samples and normalized to the urinary creatinine concentration.

5. Evaluation of Arterial Wall Stiffness

Systemic arterial wall stiffness was evaluated with the cardio-ankle vascular index (CAVI). The CAVI was determined with a VaSera CAVI instrument (Fukuda Denshi Co. Ltd., Tokyo, Japan) and methods described previously¹³. The average coefficient of variation of the CAVI is less than 5%, which is sufficiently small for clinical usage and indicates that CAVI has good reproducibility¹³.

6. Statistical Analysis

A commercially available statistical software program (StatView-J 5.0; Hulus Inc., Tokyo, Japan) was used for all statistical analyses. Continuous variables were expressed as means $\pm$ standard deviations. Between-group comparisons for continuous variables were performed with Student's t-test. The correlation coefficient was estimated with Spearman's rank correlation analysis. Multivariate analysis was performed with multiple regression analysis. A p value of <0.05 was considered to indicate statistical significance.

Results

Baseline clinical characteristics are shown in **Table 1**. The mean AIX was 86%, but the AIX was widely distributed, from 46% to 130%. The mean eGFR was 76 mL/min/1.73 m². The relationships of AIX with various clinical variables and

Table 1 Baseline clinical characteristics

Age (yrs)	68 ± 12
Male/Female	122/199
Height (cm)	155 ± 9
Hypertension (%)	250 (78)
Hyperlipidemia (%)	189 (59)
Diabetes mellitus (%)	83 (26)
Body mass index (kg/m ²)	23.6 ± 3.8
Smoking (%)	62 (19)
Systolic blood pressure (mmHg)	142 ± 18
Diastolic blood pressure (mmHg)	86 ± 11
Pulse rate (/minutes)	70 ± 11
Total cholesterol (mg/dL)	201 ± 98
Low-density lipoprotein cholesterol (mg/dL)	126 ± 28
Triglyceride (mg/dL)	111 ± 48
High-density lipoprotein cholesterol (mg/dL)	53 ± 9
Fasting blood glucose (mg/dL)	108 ± 26
Immunoreactive insulin (μg/mL)	7.0 ± 4.8
Hemoglobin A1c (%)	5.2 ± 1.0
Homeostasis assessment insulin resistance	1.9 ± 1.5
Augmentation index (%)	86 ± 14
eGFR (mL/min/1.73 mm ²)	76 ± 15
Log-urinary albumin (mg/g Cr)	1.1 ± 0.2
Log- high sensitive C reactive protein (mg/L)	−1.1 ± 0.5
Urinary 8-isoprostaglandinF2α (pg/mg Cr)	270 ± 134
Cardio-ankle vascular index	8.9 ± 1.4
ACE-i/ARB (%)	92 (29)
Calcium-channel blockers (%)	86 (27)
β-blocker (%)	12 (4)
Statin (%)	77 (24)
Blood-sugar lowering drugs (%)	58 (18)

eGFR, estimated glomerular filtration rate; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; Continuous values are mean ± SD.

cardiovascular risk factors are shown in **Table 2**. The AIx showed significant positive correlations with age, systolic blood pressure, the hs-CRP concentration, the urinary 8-iso-prostaglandin F2α concentration, the CAVI, and the urinary albumin concentration. Conversely, the AIx showed significant negative correlations with the male sex, height, pulse rate, and the eGFR. The AIx showed no significant correlations with the serum lipid, blood glucose, or blood insulin concentration; the hemoglobinA1c; the HOMA-IR; or cardiovascular risk factors, such as hypertension, hyperlipidemia, diabetes mellitus, and smoking habits. The AIx showed no significant relations with medications, such as antihypertensive drugs, statins, and blood-sugar-lowering drugs.

To further investigate the relationship of AIx with

kidney function and atherosclerosis, multiple regression analysis was performed to evaluate the ability of ten factors (systolic blood pressure, pulse rate, smoking, age, height, gender (male=1 and female=0), eGFR, urinary albumin concentration, hs-CRP concentration, and urinary 8-isoprostaglandin F2α concentration) to explain the augmentation index as a subordinate factor. Six factors (gender, urinary 8-iso-prostaglandin F2α concentration, hs-CRP concentration, pulse rate, urinary albumin concentration, and height) were selected as independent variables for AIx (**Table 3**). However, age, systolic blood pressure, CAVI, and eGFR were not selected. Multiple regression analysis was also performed for sex differences. Five factors (urinary 8-iso-prostaglandin F2α concentration, hs-CRP concentration, pulse rate, urinary albumin

Table 2 Relationships between augmentation index and various clinical parameters

	r	p value
Age	0.21	<0.001
Gender (Male=1, Female=0)	-0.23	<0.001
Height	-0.24	<0.001
Hypertension (Yes=1, No=0)	0.13	NS
Hyperlipidemia (Yes=1, No=0)	0.11	NS
Diabetes mellitus (Yes=1, No=0)	0.06	NS
Body mass index	-0.07	NS
Smoking (Yes=1, No=0)	0.11	NS
Systolic blood pressure	0.18	<0.01
Diastolic blood pressure	0.02	NS
Pulse rate	-0.31	<0.001
Total cholesterol	-0.03	NS
Low-density lipoprotein cholesterol	-0.02	NS
Triglyceride	-0.03	NS
High-density lipoprotein cholesterol	0.02	NS
Fasting blood glucose	-0.09	NS
Immunoreactive insulin	-0.10	NS
Hemoglobin A1c	-0.09	NS
Homeostasis assessment insulin resistance	-0.09	NS
eGFR	-0.15	<0.01
Log-urinary albumin	0.30	<0.001
Log- high sensitive C reactive protein	0.28	<0.001
Urinary 8-isoprostaglandinF2 α	0.31	<0.001
Cardio-ankle vascular index	0.17	<0.01
ACE-i/ARB (Yes=1, No=0)	-0.09	NS
Calcium-channel blockers (Yes=1, No=0)	-0.04	NS
β -blocker (Yes=1, No=0)	0.11	NS
Statin (Yes=1, No=0)	-0.10	NS
Blood-sugar lowering drugs (Yes=1, No=0)	0.05	NS

Abbreviation as in Table 1.

Table 3 Results of multiple regression analysis of augmentation index

	Standard regression coefficient	t value	p value
Acceptable factor			
Gender (Male=1, Female=0)	-0.25	-5.2	<0.001
U-8-isoPGF2 α	0.24	5.1	<0.001
Log-hs-CRP	0.23	4.9	<0.001
Pulse rate	-0.21	-4.5	<0.001
Log-U-Alb	0.18	3.6	<0.01
Height	-0.16	-3.2	<0.01

R²=0.34, F value=32.5, p<0.001, (n=321)

concentration, and height) were selected as independent variables for the AIx in both male subjects and female subjects.

Discussion

The AIx showed significant relationships with markers of kidney function. The AIx also showed significant relationships with markers of

atherosclerosis, such as the hs-CRP and urinary 8-iso-prostaglandin F₂ α concentrations, and the CAVI. Multiple regression analysis indicated that urinary albumin, hs-CRP, and urinary 8-iso-prostaglandin F₂ α concentrations were independent variables for the AIx as a subordinate factor, following adjustments for gender, height, and pulse rate, which are known to strongly affect the AIx.

Several studies have indicated the importance of a decrease in GFR during cardiovascular events^{1,2,14}, and the eGFR is commonly used worldwide to evaluate the stage of chronic kidney disease. In the present study, the AIx showed a significant negative correlation with the eGFR on simple linear regression analysis; however, the correlation coefficient was only -0.15, and multiple regression analysis indicated that the eGFR was not an independent variable for AIx as a subordinate factor. Therefore, AIx must be considered a variable different from the GFR, and the measurement of both eGFR and AIx would be of benefit when evaluating cardiovascular risk in patients with preserved kidney function.

Microalbuminuria is an important cardiovascular risk factor, and epidemiological studies have revealed that an increase in urinary albumin concentration during the normoalbuminuria phase is also an important risk factor for cardiovascular disease^{15,16}. Therefore, from the perspective of preventing cardiovascular disease, urinary albumin concentration should be decreased to the lowest possible level. The urinary albumin concentration is considered to reflect not only glomerular hypertension but also systemic endothelial function¹⁷.

Conversely, Shirai et al. have reported that the CAVI, which is essentially the stiffness parameter of a long segment of arterial wall, is unaffected by blood pressure at the time of measurement¹³. In the present study, both the urinary albumin concentration and the CAVI showed significant positive correlations with the AIx on simple linear regression analysis; however, multiple regression analysis indicated that the CAVI was not an independent variable for AIx as a subordinate factor, even though urinary albumin concentration was. In fact, several clinical studies have found that the AIx

is elevated when arterial wall stiffness increases¹⁸; however, the present data indicate that the AIx does not reflect arterial wall stiffness in patients without apparent kidney disease. Soga et al. have also reported a close relationship between the AIx and endothelial dysfunction, which was estimated by means of flow-mediated vasodilation in the brachial artery¹⁹. Endothelial dysfunction is the first step in the progression to atherosclerosis; furthermore, endothelial dysfunction is independently related to future cardiovascular events. Therefore, AIx could potentially be an important target factor for the prevention of cardiovascular events which is not detectable by evaluation of arterial stiffness in patients with preserved kidney function.

Recent basic and clinical studies have shown that chronic inflammation and oxidative stress in vivo contribute to the development of atherosclerosis²⁰⁻²². In the present study, multiple regression analysis revealed independent associations between the AIx and the hs-CRP concentration, as a marker of inflammation, and with the urinary 8-iso-prostaglandin F₂ α concentration, as a marker of oxidative stress. Several clinical studies have also found that the serum CRP and isoprostane concentrations have close relationships with the AIx^{23,24}. These results suggest that an increase in inflammation or oxidative stress in vivo plays an important role in increasing the arterial wave reflection. Therefore, early intervention, to decrease inflammation and oxidative stress, could prevent cardiovascular disease resulting from a decrease in the AIx in patients with preserved kidney function.

The AIx is decreased by vasodilators, such as calcium channel blockers, angiotensin II receptor antagonists, and nitrates^{25,26}. Conversely, various drugs, including vasodilators and statins, decrease inflammation and oxidative stress in vivo^{27,28}. In the present cross-sectional study, AIx showed no significant relation with medications, such as antihypertensive drugs or statins. However, prospective study is warranted to examine the effectiveness of these drugs from the viewpoint of the AIx, inflammation, and oxidative stress; consequently, new applications for these drugs for preventing cardiovascular disease will likely be

discovered.

The present study had several limitations. Treatment with antihypertensive drugs was stopped 24 hours or more before measurement to avoid influencing AIx. However, 24 hours was not enough to avoid the effects of long-acting drugs, such as amlodipine. The AIx showed significant relationships with various markers of atherosclerosis. However, this was a cross-sectional study in patients with no history of cardiovascular events. Therefore, it remains unclear whether elevation of the AIx is a cardiovascular risk factor in patients with preserved kidney function. Prospective studies involving larger numbers of subjects are necessary to confirm the significance of the AIx as a risk factor for primary cardiovascular events in patients with preserved kidney function, and cut-off values for the AIx should be determined to identify high-risk patients. Furthermore, an extensive examination of basic and clinical studies investigating the significance of the AIx is required.

In conclusion, results of the present study indicate that the AIx reflects oxidative stress, inflammation, and the urinary albumin concentration in patients with preserved kidney function and suggest that an elevated AIx can be used to predict primary cardiovascular events in patients with preserved kidney function.

Conflicts of interest: None

References

1. Coresh J, Selvin E, Stevens LA, et al.: Prevalence of chronic kidney disease in the United States. *JAMA* 2007; 298: 2038–2047.
2. Yamagata K, Ishida K, Sairenchi T, et al.: Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. *Kidney Int* 2007; 71: 159–166.
3. Curhan GC: Prediabetes, prehypertension ... is it time for pre-CKD? *Clin J Am Soc Nephrol* 2010; 5: 557–559.
4. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A: Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. *Hypertens Res* 2007; 30: 219–228.
5. Williams B, Lacy PS, Thom SM, et al.: CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006; 113: 1213–1225.
6. Roman MJ, Devereux RB, Kizer JR, et al.: Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. *Hypertension* 2007; 50: 197–203.
7. London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME: Arterial wave reflections and survival in end-stage renal failure. *Hypertension* 2001; 38: 434–438.
8. Otsuka T, Kawada T, Ibuki C, Kusama Y: Radial arterial wave reflection is associated with the MEGA risk prediction score, an indicator of coronary heart disease risk, in middle-aged men with mild to moderate hypercholesterolemia. *J Atheroscler Thromb* 2010; 17: 688–694.
9. Kohara K, Tabara Y, Oshiumi A, Miyawaki K, Kobayashi T, Miki T: Radial augmentation index: a useful and easily obtainable parameter for vascular aging. *Am J Hypertens* 2005; 18: 11S–14S.
10. Imai E, Horio M, Nitta K, et al.: Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. *Clin Exp Nephrol* 2007; 11: 41–50.
11. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499–502.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412–419.
13. Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). *J Atheroscler Thromb* 2006; 13: 101–107.
14. Ninomiya T, Kiyohara Y, Tokuda Y, et al.: Japan Arteriosclerosis Longitudinal Study Group: Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. *Circulation* 2008; 118: 2694–2701.
15. Gerstein HC, Mann JF, Yi Q, et al.: HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001; 286: 421–426.
16. Arnlöv J, Evans JC, Meigs JB, et al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation* 2005; 112: 969–975.
17. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. *Lancet* 1992; 340: 319–323.
18. Oliver JJ, Webb DJ: Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. *Arterioscler Thromb Vasc Biol* 2003; 23: 554–566.

19. Soga J, Nakamura S, Nishioka K, et al: Relationship between augmentation index and flow-mediated vasodilation in the brachial artery. *Hypertens Res* 2008; 31: 1293-1298.
20. Ross R: Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999; 340: 115-126.
21. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. *Circulation* 2002; 105: 1135-1143.
22. Kondo T, Hirose M, Kageyama K: Roles of oxidative stress and redox regulation in atherosclerosis. *J Atheroscler Thromb* 2009; 16: 532-538.
23. Booth AD, Wallace S, McEniery CM, et al: Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. *Arthritis Rheum* 2004; 50: 581-588.
24. Spence VA, Kennedy G, Belch JJ, Hill A, Khan F: Low-grade inflammation and arterial wave reflection in patients with chronic fatigue syndrome. *Clin Sci (Lond)* 2008; 114: 561-566.
25. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE: AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. *J Hypertens* 2002; 20: 2423-2428.
26. Murgu JP, Westerhof N, Giolma JP, Altobelli SA: Aortic input impedance in normal man: relationship to pressure wave forms. *Circulation* 1980; 62: 105-116.
27. Kinlay S, Schwartz GG, Olsson AG, et al: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators : High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. *Circulation* 2003; 108: 1560-1566.
28. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K: Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. *Clin Exp Hypertens* 2008; 3: 267-276.

(Received, February 2, 2012)
(Accepted, April 23, 2012)